Entero-insular axis and diabetes mellitus.
1. The incretin effect (i.e. the difference between the insulin response after oral and i.v. glucose) is reduced in type 2 diabetes although GIP secretion is normal or exaggerated. This suggests an insensitivity of the diabetic B-cell to GIP. However, it could also indicate the lack of another not yet defined "incretin". 2. While CCK is a potent incretin in rats and dogs, physiological concentrations of this hormone do not stimulate insulin secretion in man in presence of elevated blood levels of glucose or phenylalanine in the physiological range. It also does not interact with GIP. 3. Glucagon-like peptide I (7-36) is a potent glucose-dependent stimulator of insulin secretion in animals and man. Preliminary data suggest release after oral glucose despite localization of the GLPI containing cells predominantly in the ileum and colon. More data are needed before GLPI (7-36) can be regarded as a physiological incretin and its role in type 2 diabetes assessed.
Creutzfeldt
W
W
Department of Medicine, University of Göttingen, Germany.
D000818:Animals; D002766:Cholecystokinin / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000503:physiopathology*; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007422:Intestines / Q000503:physiopathology*; D007515:Islets of Langerhans / Q000378:metabolism / Q000503:physiopathology*; D010446:Peptide Fragments / Q000502:physiology
D007328:Insulin; D010446:Peptide Fragments; C061970:glucagon-like peptide 1 (7-36); D005749:Gastric Inhibitory Polypeptide; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D002766:Cholecystokinin